Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NY105 is an investigational radiopharmaceutical PET imaging tracer developed by the Affiliated Hospital of Jiangnan University in China. It consists of the compound NY105 labeled with Gallium-68 (68Ga), a radioactive isotope used in positron emission tomography (PET) imaging. The agent is administered intravenously at tracer doses to evaluate its safety and biodistribution in patients with cancer. Currently, it is being investigated in an Early Phase 1 clinical trial (NCT05691881) to assess tissue and organ uptake using standardized uptake values (SUVs). While the specific biological target of the NY105 moiety has not been publicly disclosed, it is characterized as a small-molecule diagnostic probe for oncological imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-NY105.